| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
55,795 |
45,275 |
$3.31M |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
21,741 |
16,789 |
$2.05M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
13,859 |
10,713 |
$1.10M |
| 87631 |
|
16,779 |
14,841 |
$977K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
17,594 |
14,152 |
$712K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
17,274 |
12,425 |
$656K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
10,875 |
8,550 |
$569K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
3,158 |
2,512 |
$478K |
| 87486 |
|
18,620 |
15,720 |
$423K |
| 87581 |
|
18,616 |
15,720 |
$423K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
44,387 |
19,325 |
$385K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
8,063 |
7,597 |
$328K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
30,221 |
25,566 |
$305K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
30,493 |
23,119 |
$232K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
14,351 |
10,144 |
$170K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,673 |
1,308 |
$95K |
| 87500 |
|
5,291 |
4,459 |
$94K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
1,488 |
970 |
$50K |
| 87640 |
|
2,766 |
1,382 |
$27K |
| 87481 |
|
1,543 |
928 |
$24K |
| 71046 |
Radiologic examination, chest; 2 views |
2,170 |
1,592 |
$23K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
17,512 |
13,666 |
$21K |
| 87529 |
|
474 |
384 |
$20K |
| 87653 |
|
1,198 |
727 |
$14K |
| 87511 |
|
478 |
384 |
$10K |
| 99051 |
|
728 |
672 |
$9K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
478 |
384 |
$8K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
11,772 |
8,853 |
$7K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
492 |
395 |
$7K |
| 81003 |
|
3,016 |
2,495 |
$6K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
128 |
106 |
$5K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
464 |
370 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,200 |
1,581 |
$2K |
| 99305 |
|
30 |
18 |
$806.40 |
| 99201 |
|
44 |
22 |
$756.00 |
| 36415 |
Collection of venous blood by venipuncture |
811 |
609 |
$677.20 |
| 82962 |
|
391 |
309 |
$620.44 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
106 |
86 |
$562.76 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
23 |
19 |
$557.60 |
| 74018 |
|
35 |
29 |
$454.61 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
78 |
56 |
$420.00 |
| 74019 |
|
21 |
16 |
$299.46 |
| 93000 |
|
39 |
29 |
$201.60 |
| 87807 |
|
13 |
12 |
$112.10 |
| 94760 |
|
268 |
224 |
$88.96 |
| 81025 |
|
16 |
14 |
$32.60 |
| 96127 |
|
27 |
25 |
$2.61 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
18 |
16 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
64 |
44 |
$0.00 |